PRE-TREATMENT WITH IDELALISIB MARKEDLY REDUCES RITUXIMAB INFUSION-RELATED REACTIONS AND INFUSION INTERRUPTIONS IN PATIENTS WITH CLL

被引:0
|
作者
Hillmen, P. [1 ]
Furman, R. R. [2 ]
Coutre, S. E. [3 ]
Sharman, J. P. [4 ,5 ]
Pagel, J. M. [6 ]
Barrientos, J. C. [7 ]
Zelenetz, A. D. [8 ]
Kipps, T. J. [9 ]
Flinn, I. [10 ]
Ghia, P. [11 ,12 ]
Eradat, H. A. [13 ]
Lamanna, N. [14 ]
Coiffier, B. [15 ]
Pettitt, A. [16 ]
Ye, W. [17 ]
Jahn, T. M. [17 ]
Dubowy, R. [17 ]
O'Brien, S. M. [18 ]
Hallek, M. J. [19 ]
Cheson, B. D. [20 ]
机构
[1] Leeds Teaching Hosp, St James Inst Oncol, Leeds, W Yorkshire, England
[2] Weill Cornell Med Coll, New York, NY USA
[3] Stanford Univ, Sch Med, Stanford Canc Ctr, Stanford, CA 94305 USA
[4] Willamette Valley Canc Inst, Springfield, OR USA
[5] Res Ctr US Oncol Res, Springfield, IL USA
[6] Fred Hutchinson Canc Res Ctr, Seattle, WA 98104 USA
[7] Hofstra North Shore LIJ Sch Med, Hempstead, NY USA
[8] Mem Sloan Kettering Canc Ctr, New York, NY 10021 USA
[9] Univ Calif San Diego, Sch Med, San Diego, CA 92103 USA
[10] Sarah Cannon Res Inst, Nashville, TN USA
[11] Univ Vita Salute San Raffaele, Milan, Italy
[12] Ist Sci San Raffaele, Milan, Italy
[13] Univ Calif Los Angeles, David Geffen Sch Med, Los Angeles, CA 90095 USA
[14] Mem Sloan Kettering Canc Ctr, New York, NY 10021 USA
[15] Lyon Sud Univ Hosp, Pierre Benite, France
[16] Univ Liverpool, Liverpool L69 3BX, Merseyside, England
[17] Gilead Sci Inc, Foster City, CA 94404 USA
[18] Univ Texas MD Anderson Canc Ctr, Houston, TX 77030 USA
[19] Bonn Univ Hosp Cologne, Cologne, Germany
[20] Georgetown Univ, Med Ctr, Washington, DC 20007 USA
关键词
D O I
暂无
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
P236
引用
收藏
页码:55 / 55
页数:1
相关论文
共 50 条
  • [1] Pre-treatment with Idelalisib markedly reduces Rituximab infusion-related reactions and infusion interruptions in patients with CLL
    Hallek, M.
    Hillmen, P.
    Furman, R. R.
    Coutre, S. E.
    Sharman, J. P.
    Pagel, J. M.
    Barrientos, J. C.
    Zelenetz, A. D.
    Kipps, T. J.
    Flinn, I. W.
    Ghia, P.
    Eradat, H.
    Erwin, T.
    Lamanna, N.
    Coiffier, B.
    Pettitt, A. R.
    O'Brien, S. M.
    Cheson, B. D.
    Ruppert, S.
    Kroenig, H.
    Schuster, A.
    [J]. ONCOLOGY RESEARCH AND TREATMENT, 2014, 37 : 52 - 53
  • [3] Role of CD20 expression and other pre-treatment risk factors in the development of infusion-related reactions in patients with CLL treated with obinutuzumab
    Freeman, C. L.
    Dixon, M.
    Houghton, R.
    Kreuzer, K-A
    Fingerle-Rowson, G.
    Herling, M.
    Humphrey, K.
    Boettcher, S.
    de Costa, C. S.
    Iglesias, V.
    Stilgenbauer, S.
    Gribben, J.
    Hallek, M.
    Goede, V.
    [J]. LEUKEMIA, 2016, 30 (08) : 1763 - 1766
  • [4] Role of CD20 expression and other pre-treatment risk factors in the development of infusion-related reactions in patients with CLL treated with obinutuzumab
    C L Freeman
    M Dixon
    R Houghton
    K-A Kreuzer
    G Fingerle-Rowson
    M Herling
    K Humphrey
    S Böttcher
    C S de Costa
    V Iglesias
    S Stilgenbauer
    J Gribben
    M Hallek
    V Goede
    [J]. Leukemia, 2016, 30 : 1763 - 1766
  • [5] Infusion-related reactions to infliximab (remicade®) in patients with rheumatoid arthritis:: Relationship to dose, anti-histamine pre-treatment and infusion number
    Wasserman, MJ
    Weber, DA
    Guthrie, JA
    Mitroi, E
    Bykerk, V
    Lee, P
    Keystone, EC
    [J]. JOURNAL OF RHEUMATOLOGY, 2003, 30 (08) : 1888 - 1888
  • [7] Infusion-related reactions to rituximab: frequency, mechanisms and predictors
    Paul, Franciane
    Cartron, Guillaume
    [J]. EXPERT REVIEW OF CLINICAL IMMUNOLOGY, 2019, 15 (04) : 383 - 389
  • [8] Cytokine release in patients with CLL treated with obinutuzumab and possible relationship with infusion-related reactions
    Freeman, Ciara L.
    Morschhauser, Franck
    Sehn, Laurie
    Dixon, Mark
    Houghton, Richard
    Lamy, Thierry
    Fingerle-Rowson, Guenter
    Wassner-Fritsch, Elisabeth
    Gribben, John G.
    Hallek, Michael
    Salles, Gilles
    Cartron, Guillaume
    [J]. BLOOD, 2015, 126 (24) : 2646 - 2649
  • [9] A clinical prediction model for infusion-related reactions to rituximab in patients with B cell lymphomas
    Hayama, Tatsuya
    Miura, Katsuhiro
    Uchiike, Akihiro
    Nakagawa, Masaru
    Tsutsumi, Daisuke
    Sakagami, Masashi
    Yoshida, Yoshikazu
    Takei, Masami
    [J]. INTERNATIONAL JOURNAL OF CLINICAL PHARMACY, 2017, 39 (02) : 380 - 385
  • [10] A clinical prediction model for infusion-related reactions to rituximab in patients with B cell lymphomas
    Tatsuya Hayama
    Katsuhiro Miura
    Akihiro Uchiike
    Masaru Nakagawa
    Daisuke Tsutsumi
    Masashi Sakagami
    Yoshikazu Yoshida
    Masami Takei
    [J]. International Journal of Clinical Pharmacy, 2017, 39 : 380 - 385